A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies

Histochemistry and Cell Biology

Volumn 142, Issue 4, 2014, Pages 361-371

  Huber, K ^a   Aichler, M ^a   Sun, N ^a   Buck, A ^a   Li, Z ^b   Fernandez, I E ^c   Hauck, S M ^a   Zitzelsberger, H ^a   Eickelberg, O ^c   Janssen, K P ^d   Keller, U ^b   Walch, A ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Drug imaging; Ex vivo tissue model; MALDI imaging; MALDI FT ICR

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; AFATINIB; ALPHA CYANO 4 HYDROXYCINNAMIC ACID; ERLOTINIB; IRINOTECAN; PIRFENIDONE; CAMPTOTHECIN; PYRIDONE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TISSUE LEVEL; EX VIVO STUDY; IN VIVO STUDY; LIVER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; NUDE MOUSE; ORAL DRUG ADMINISTRATION;

ANIMALIA; MUS;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; CAMPTOTHECIN; IN VITRO TECHNIQUES; LIVER; MICE; MICE, INBRED C57BL; MICE, NUDE; MODELS, ANIMAL; MOLECULAR STRUCTURE; PYRIDONES; QUINAZOLINES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84908569711     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-014-1223-0     Document Type: Article

References (26)

1. Balluff B, Schöne C, Höfler H, Walch A (2011) MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem Cell Biol 136(3):227–244
2. Castellino S, Groseclose MR, Wagner D (2011) MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis 3(21):2027–2441
3. Chughtai K, Heeren RM (2010) Mass spectrometric imaging for biomedical tissue analysis. Chem Rev 110(5):3237–3277
4. Ellis SR, Bruinen AL, Heeren RM (2014) A critical evaluation of the current state-of-the-art in quantitative imaging mass spectrometry. Anal Bioanal Chem 406(5):1275–1289
5. Goodwin RJ, Mackay CL, Nilsson A, Harrison DJ, Farde L, Andren PE, Iverson SL (2011) Qualitative and quantitative MALDI imaging of the positron emission tomography ligands raclopride (a D2 dopamine antagonist) and SCH 23390 (a D1 dopamine antagonist) in rat brain tissue sections using a solvent-free dry matrix application method. Anal Chem 83(24):9694–9701
6. Gosselin LE, Williams JE, Personius K, Farkas GA (2007) A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone. Muscle Nerve 35(2):208–216
7. Groseclose MR, Castellino S (2013) A mimetic tissue model for the quantification of drug distributions by MALDI imaging mass spectrometry. Anal Chem 85(21):10099–10106
8. Grüner BM, Ardito CM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, DelGiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou G, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT (2012) EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22(3):304–317
9. Hamm G, Bonnel D, Legouffe R, Pamelard F, Delbos JM, Bouzom F, Stauber J (2012) Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor. J Proteomics 75(16):4952–4961
10. Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, Oku H, Miyazaki M, Kadota J, Kohno S (2004) Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 24(1):57–65
11. Källback P, Shariatgorji M, Nilsson A, Andrén PEJ (2012) Novel mass spectrometry imaging software assisting labeled normalisation and quantitation of drugs and neuropeptides directly in tissue sections. J Proteomics 75(16):4941–4951
12. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51(16):4187–4191
13. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, Lum BL, Prakash C (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34(3):420–426
14. MacAleese L, Stauber J, Heeren RM (2009) Perspectives for imaging mass spectrometry in the proteomics landscape. Proteomics 9(4):819–834
15. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16(10):1688–1694
16. Murakami M, Zhao S, Zhao Y, Yu W, Fatema CN, Nishijima KI, Yamasaki M, Takiguchi M, Tamaki N, Kuge Y (2013) Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model. Oncol Lett 6(3):667–672
17. Neubert P, Walch AK (2013) Current frontiers in clinical research application of MALDI imaging mass spectrometry. Expert Rev Proteomics 10(3):259–273
18. Nilsson A, Fehniger TE, Gustavsson L, Andersson M, Kenne K, Marko-Varga G, Andrén PE (2010) Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PLoS ONE 5(7):e11411
19. Norris JL, Caprioli RM (2013) Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem Rev 113(4):2309–2342
20. Pirman DA, Reich RF, Kiss A, Heeren RM, Yost RA (2013) Quantitative MALDI tandem mass spectrometric imaging of cocaine from brain tissue with a deuterated internal standard. Anal Chem 85(2):1081–1089
21. Prideaux B, Stoeckli M (2012) Mass spectrometry imaging for drug distribution studies. J Proteomics 75(16):4999–5013
22. Schwartz SA, Reyzer ML, Caprioli RM (2003) Direct tissue analysis using matrix-assisted laser desorption/ionisation mass spectrometry: practical aspects of sample preparation. J Mass Spectrom 38(7):699–708
23. Stoeckli M, Staab D, Schweitzer A (2007) Compound and metabolite distribution measured by MALDI mass spectrometry imaging in whole-body tissue sections. Int J Mass Spectrom 160(2–3):195–202
24. Sun N, Walch A (2013) Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels. Histochem Cell Biol 140(2):39–104
25. Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Al-Shahrour F, Alexander D, Wong K, Van Dyke T (2012) Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer Res 72(22):5921–5933
26. Zaima N, Hayasaka T, Goto-Inoue N, Setou M (2010) Matrix-assisted laser desorption/ionisation imaging mass spectrometry. Int J Mol Sci 11(12):5040–5055